Phase II Study: the proportion of patients with overall Hb response by Week 24~Phase III study: the proportion of patients who achieve a durable response by Week 24
Phase II Study: To evaluate the safety and preliminary efficacy of HMPL-523 in adult patients with wAIHA~Phase III Studies: Confirmation of Efficacy safety and of HMPL-523 in Adult Patients With wAIHA